A Phase I, Open-label Study to Assess the Safety and Tolerability of Doses of Olaparib Tablet in Japanese Patients With Advanced Solid Malignancies
MTD - maximum tolerated dose
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Investigation of the safety and tolerability of olaparib tablet by assessing of CTCAE (Common Terminology Criteria Adverse Events) grade in Japanese patients with advanced solid malignancies.
Up to 11 months.
Anitra Fielding, M.B.
Global Medicines Development
Japan: Ministry of Health, Labor and Welfare